Palo Alto, CA
Ticker: Nasdaq: AMGN
KAI Pharmaceuticals is a drug discovery and development company with clinical-stage programs in secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease. KAI’s expertise is in the selective modulation of intracellular protein:protein interactions via the delivery of peptide drugs into the cell. The company has applied its core technology to discover inhibitors and activators for members of the protein kinase C (PKC) family of isozymes. In July 2012, Amgen acquired KAI Pharmaceuticals to further develop KAI’s drug to treat kidney disease.